Quiz

Article

Clinician Quiz: AAO Guidelines for Inherited Retinal Degenerations

Test your knowledge with this clinician quiz! In this quiz, we test your knowledge on clinical assessment recommendations for patients with inherited retinal diseases based on 2022 guidelines from the American Academy of Ophthalmology.

Quiz Time Graphic | Image Credit: HCPLive

The American Academy of Ophthalmology (AAO) outlines recommendations for managing inherited retinal degenerations (IRDs), detailing testing procedures and timing for patients across four IRD classes. The guidelines emphasize the importance of adapted testing for pediatric cases, underscore the essential role of genetic testing and counseling on conforming diagnosis, and aim to optimize patient care with eligibility for clinical trials or gene therapies. This document is a comprehensive resource to guide the management of patients with IRDs and notes final treatment decisions are based on the needs of individual patients.

In this clinician quiz, test your knowledge of the clinical recommendations for people with IRDs in the 2022 American Academy of Ophthalmology Guidelines on Clinical Assessment of Patients with Inherited Retinal Degeneration.

Which of the following is NOT one of the four major types of Inherited Retinal Degenerations (IRDs) encountered clinically?


References

Guidelines on clinical assessment of patients with inherited retinal degenerations - 2022. American Academy of Ophthalmology. October 6, 2022. Accessed February 14, 2024. https://www.aao.org/education/clinical-statement/guidelines-on-clinical-assessment-of-patients-with.

Related Videos
Brigit Vogel, MD: Exploring Geographical Disparities in PAD Care Across US| Image Credit: LinkedIn
Eric Lawitz, MD | Credit: UT Health San Antonio
| Image Credit: X
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Stephen Nicholls, MBBS, PhD | Credit: Monash University
Marianna Fontana, MD, PhD: Nex-Z Shows Promise in ATTR-CM Phase 1 Trial | Image Credit: Radcliffe Cardiology
Zerlasiran Achieves Durable Lp(a) Reductions at 60 Weeks, with Stephen J. Nicholls, MD, PhD | Image Credit: Monash University
Gaith Noaiseh, MD: Nipocalimab Improves Disease Measures, Reduces Autoantibodies in Sjogren’s
4 experts are featured in this series.
© 2024 MJH Life Sciences

All rights reserved.